You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Hypoxia Imaging of Uterine Cervix Carcinoma With 18F-FETNIM PET/CT

Vercellino, Laetitia MD*; Groheux, David MD*; Thoury, Anne MD; Delord, Marc MS; Schlageter, Marie-Hélène PharmD§; Delpech, Yann MD; Barré, Emmanuelle PharmD*; Baruch-Hennequin, Valérie MD; Tylski, Perrine PhD*; Homyrda, Laurence§; Walker, Francine MD; Barranger, Emmanuel MD, PhD; Hindié, Elif MD, PhD*

Clinical Nuclear Medicine:
doi: 10.1097/RLU.0b013e3182638e7e
Original Articles
Abstract

Purpose: Our aims were to assess the feasibility of imaging hypoxia in cervical carcinoma with 18F-fluoroerythronitroimidazole (18F-FETNIM) and to compare 18F-FETNIM uptake with metabolic uptake of 18F-FDG.

Patients and Methods: We included 16 patients with cervical carcinoma. After imaging with FDG, 18F-FETNIM PET/CT was performed and tumor-to-muscle (T/M) ratio uptake was assessed. 18F- FETNIM uptake was correlated to FDG uptake and osteopontin (OPN), a marker of hypoxia, and patients’ outcomes.

Results: All tumors were detected by 18F-FDG PET. 18F-FETNIM T/M ratios ranged from 1.3 to 5.4. There was no significant correlation between 18F-FETNIM and 18F-FDG uptake. High 18F-FETNIM uptake (T/M > 3.2) was associated with reduced progression-free survival (log-rank = 0.002) and overall survival (log-rank = 0.02). Osteopontin ranged from 39 to 662 μg/L (median, 102.5 μg/L). Patients with OPN greater than 144 μg/L had reduced progression-free survival compared with those with OPN less than 144 μg/L (log-rank = 0.03). We found no significant correlation between 18F-FETNIM uptake and OPN blood levels.

Conclusions: Our preliminary results showed that a high uptake of 18F-FETNIM was associated with a worse progression-free and overall survival.

Author Information

From the Departments of *Nuclear Medicine and †Gynaecology Obstetrics Lariboisière, Hospital Saint Louis APHP; ‡Department of Biostatistics/Bioinformactics, Universitary Institute of Hematology Paris VII; Departments of §Cellular Biology and ∥Oncology-Radiotherapy, Saint Louis Hospital APHP Paris; and ¶Department of pathology Bichat Hospital APHP Paris, France.

Received for publication March 2, 2012 and revision accepted April 23, 2012.

Conflicts of interest and sources of funding: none declared.

Professor Jean-luc Moretti, the main investigator of this study, passed away on December 21, 2010. This work is dedicated to him.

Reprints: Laetitia Vercellino, MD, Hôpital Saint Louis 1 avenue Claude Vellefaux 75010 Paris, France. E-mail: laetitia.vercellino@sls.aphp.fr.

© 2012 Lippincott Williams & Wilkins, Inc.